Search Results - clinical+and+disease+specializations+%3e+immunology

20 Results

Sort By:

Polymers and Nanoparticles for Intramuscular Nucleic Acid Delivery

Value Proposition:· Platform technology for prophylactic and therapeutic vaccination with large RNA payloads.· Can deliver several types of nucleic acid payloads including self-amplifying mRNA, plasmid, linear DNA, siRNA, miRNA, mRNA.· Adaptable as a therapeutic delivery strategy for genetic, musculoskeletal, and neurological disorders.Unmet Need:Vaccinology...

Published: 5/10/2024 | Inventor(s): Jordan Green, David Wilson, Stephany Tzeng, Yuan Rui, Sarah Neshat, Kathryn Luly

Keywords(s):

Category(s): Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Infectious Diseases

Nanoparticles for Delivery of Immunoregulatory Materials to T Cells

Value Proposition:· This platform improves current methods for expansion of CD4+ T-cells, which could be used in adoptive transfer therapies.· Improves modulation, activation, and expansion of T cells over current methods used for CAR T-cell therapyTechnology Description· Researchers at Johns Hopkins have developed a nanoparticle-based...

Published: 5/10/2024 | Inventor(s): Jonathan Schneck, Ariel Isser

Keywords(s):

Category(s): Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Oncology, Technology Classifications > Engineering Tech, Technology Classifications > Therapeutic Modalities

Novel Therapeutic Drug for Multiple Sclerosis

INVENTION NOVELTY This molecule, through its action on a unique target that is different from current therapeutic treatments for MS, has both immunosuppressive and neuromodulatory properties that will better prevent the progression of MS and repair the neuronal damage caused by the immune cells in MS. Currently, there are no MS drugs in the market...

Published: 5/9/2024 | Inventor(s): Paul Kim, Michael Kornberg, Peter Calabresi, Solomon Snyder

Keywords(s): Chronic Inflammatory Diseases, CNS and Neurological Disorders, Disease Indication, Multiple Sclerosis, Multiple Sclerosis (MS), Neurodegeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Polymers for Binding-Triggered Antibody Precipitation and Purification

Value PropositionResults in >97% precipitation yield, >88% elution yield of mAbsSimplified molecular design compared to elastin-like polypeptide (ELP)-based materialsDoes not need additional salt to achieve mAb precipitation and recoveryTechnology DescriptionResearchers at Johns Hopkins have developed a peptide-based platform technology using...

Published: 5/10/2024 | Inventor(s): Honggang Cui, Yi Li, David Stern, XuanKuo Xu, Lye Lin Lock, Jason Mills, Sanchayita Ghose, Zheng Jian Li

Keywords(s):

Category(s): Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Research Tools, Technology Classifications > Research Tools > Antibodies, Technology Classifications > Research Tools > Research Antibodies, Technology Classifications > Therapeutic Modalities > Antibodies, Technology Classifications > Therapeutic Modalities > Therapeutic Antibodies

Polymeric Nanoparticle Genetic Vaccines

Value PropositionVersatile immunotherapy platform with the ability to specifically target antigen presenting cells (APCs) ) following systemic delivery and without requiring targeting ligands to improve treatment efficacy. Flexibility to modulate the immune system through activation or inducing tolerance.Useful as a preventative strategy or therapeutic...

Published: 5/10/2024 | Inventor(s): Jordan Green, Elana Ben-Akiva, Johan Karlsson, Stephany Tzeng, Kelly Rhodes, Sarah Neshat

Keywords(s):

Category(s): Clinical and Disease Specializations > Autoimmunity, Clinical and Disease Specializations > Immunology, Technology Classifications > Medical Devices > Therapeutic Devices, Technology Classifications > Therapeutic Modalities > Dendrimers & Polymers, Technology Classifications > Therapeutic Modalities > Immunotherapies, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Vaccines

Albumin-Flt3L Fusion Protein to Enhance Anti-Tumor Immunity and Antigen-specific T-cell Cytotoxicity

Unmet Need: Active immunotherapy, such as anti-PD-1/PD-L1 and anti-CTLA-4 checkpoint blockage, involves the administration of molecules to mobilize host immune cells to recognize and kill tumors. Proper presentation of tumor antigens through antigen presenting cells is a prerequisite to elicit a potent immune response. Current strategies enhance antigen...

Published: 5/9/2024 | Inventor(s): T.c. Wu, Chien-Fu Hung, Brandon Lam

Keywords(s): Biologics, Cancers, Discovery/Research Tools, Disease Indication, In Vitro Research Tool, Research Instrument, Target, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Research Tools > Proteins, Ligands & Receptors, Clinical and Disease Specializations > Immunology, Technology Classifications, Clinical and Disease Specializations > Oncology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Targets

Immune cell metabolic profiling to quantify immunosuppression

Unmet Need / Invention Novelty: Treatment with immunosuppressionis required for patients who have undergone solid organ transplantation or who have autoimmune diseases but no standard test exists that can sensitively measure immune cells for the extent of suppression. There is a critical need for a sensitive approach that can quantify the degree of...

Published: 5/10/2024 | Inventor(s): Andrea Lynn Cox, Elizabeth Thompson, Justin Bailey, Katherine Cascino

Keywords(s):

Category(s): Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Transplantation

Reprogramming Aluminum Adjuvants to Tailor Immune Response

Unmet NeedVaccination is an important public health intervention that has led to the rapid decline of many infectious diseases. To maximize safety and minimize reactogenicity, vaccine development is gradually shifting from whole, inactivated vaccines to well defined subunit vaccines. However, this approach often suffers from reduced immunogenicity....

Published: 5/10/2024 | Inventor(s): Hai-Quan Mao, Gregory Howard

Keywords(s):

Category(s): Clinical and Disease Specializations > Infectious Diseases, Clinical and Disease Specializations > Immunology, Technology Classifications > Therapeutic Modalities > Vaccines

Method to Enhance Pulmonary Dendritic Cell-mediated DNA Vaccination

Unmet NeedWith lung diseases, namely influenza and lung cancer, on the rise, pulmonary vaccination is a promising approach to elicit strong immunity to inhaled pathogens and lung cancer compared to systemic immunization strategies. In particular, inhaled DNA vaccination, a rapidly developing field, can potentially promote humoral and cellular immunity...

Published: 5/9/2024 | Inventor(s): Jung Soo Suk, Yoo Chun Kim, Justin Hanes

Keywords(s): Biologics, Cancers, Disease Indication, Drug Delivery Vehicle, Immunotherapy, Infectious Diseases, Influenza, Lung Cancer, Nanoparticles, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type, Tuberculosis (TB), Vaccine

Category(s): Clinical and Disease Specializations > Infectious Diseases > Tuberculosis (TB), Clinical and Disease Specializations > Infectious Diseases > Influenza, Clinical and Disease Specializations > Immunology, Clinical and Disease Specializations > Immuno-Oncology, Clinical and Disease Specializations > Oncology > Lung Cancer, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms, Technology Classifications > Therapeutic Modalities > Vaccines

Tolerogenic Artificial Antigen-Presenting Cells

Unmet Need Autoimmune diseases are often treated with immunosuppressants that weaken the entire immune system, leaving patients vulnerable to infection. An ideal autoimmune therapy would establish immune tolerance to a specific self-antigen, while the rest of the immune system remains intact. One promising approach for regulating autoimmunity is via...

Published: 5/9/2024 | Inventor(s): Jordan Green, Kelly Rhodes, Randall Meyer, Stephany Tzeng

Keywords(s): Biologics, Drug Delivery Vehicle, Polymers, Protein, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Immunology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

1 2